Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Hormone. Institut Paoli-Calmettes, Marseille, France



Survival: 54.2 months
   
Toxicity Grade: 4
   
Treatments: Hormone
   
Drugs:
Country: France
   
City/State/Province: Marseille
   
Hospital: Institut Paoli-Calmettes
   
Journal: Link
   
Date: 2/2013

Description:
Patients:
This phase 3 study involved non-castrate (hormone-sensitive) prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 192 men with a median age of 63 years. Group B had 193 men with a median age of 64 years.

Treatment:
Patients in group A were treated with androgen-deprivation therapy (hormone therapy) and the chemotherapy agent docetaxel.

Patients in group B were treated with androgen-deprivation therapy (hormone therapy) alone.

Toxicities:
There were four treatment-related deaths in group A. Causes of death included neutropenia and infection. Grade 3-4 fatigue and erectile dysfunction were also reported.

The most severe toxicities were of grade 4 and included grade 3-4 erectile dysfunction and decreased libido.

Results:
The median overall survival for groups A and B was 58.9 and 54.2 months, respectively.

Support:
This study was partially supported by Sanofi-Aventis, Amgen, and AstaZeneca.

Correspondence: Dr. Gwenaelle Gravis; email: gravisg@ipc.unicancer.fr

E-mail to a Friend Email Physician More Information